Anthropic "Biggest Company Out There:" Cory Johnson on IPOs & SPCX "Miracle"

Cory Johnson called the SpaceX IPO "pretty unique," saying the stock holding above its IPO price despite current valuations is "kind of a miracle." He attributed the resilience to rising demand in the IPO market, citing Anthropic as evidence of strong appetite for large private tech names. The commentary is constructive for IPO sentiment, but it is opinion-based and unlikely to drive broad market moves.

Analysis

The key signal is not the specific issuer but the market microstructure around scarce, high-status private assets. When a marquee IPO can hold above issue price despite premium private-market expectations, it implies marginal capital is chasing optionality and narrative more than immediate cash flow, which tends to compress returns for later-stage private rounds while improving exit economics for venture funds and bankers. That creates a reflexive loop: stronger aftermarket performance expands the feasible IPO window for other frontier-tech names, especially AI, and can pull forward supply from companies that otherwise would have stayed private another 12-24 months.

Second-order winners are the ecosystem providers that monetize issuance volume and sentiment persistence: underwriters, late-stage crossover funds, and venture secondary sellers. The losers are investors relying on scarcity premiums in pre-IPO rounds, because the market may be repricing the required discount to public comps downward; that can pressure follow-on financing terms for companies with weaker growth or less obvious AI adjacency. A sustained bid also narrows the gap between private valuations and public multiples, which is constructive for any holding company or SPAC structure trying to justify a premium via future embedded optionality.

The risk is that this is a momentum-driven regime, not a durable fundamental reset. If one or two high-profile IPOs break below issue price in the first 30-60 days, the same positioning that lifted the tape can unwind quickly as crossover funds de-risk and retail demand fades. The contrarian view is that investors may be overpaying for a very small set of “category winner” names while ignoring the deteriorating quality of the broader IPO pipeline; in that setup, the first crack usually comes not from the headline names but from second-tier deals that can’t clear the same valuation bar.

Key Decisions for Investors

• Long IPO secondary basket via underwriters and active bookrunners over the next 1-3 months; fade any pullback in issuance names on the thesis that deal volume, not just price, is the main revenue lever.
• Buy downside protection on a broad IPO ETF/IPO proxy into the next 30-90 days: if the window stays open, the bleed is limited; if a marquee deal gaps down, beta risk should reprice fast.
• Pair trade: long AI-adjacent late-stage private exposure, short a basket of weaker non-AI growth comps in the public market, targeting a 2-4 month convergence as investors pay up only for perceived scarcity.
• For venture/growth books, trim secondary in names likely to be next in line for listing over the next 6-12 months; the current tape may be the best exit multiple available before the market demands proof.
• Monitor first 10 trading days performance of the next 2-3 high-profile IPOs; a break below offer price would be the trigger to reduce risk broadly across IPO/SPAC exposure.